Critical Contrast: Vaso (OTCMKTS:VASO) & Sight Sciences (NASDAQ:SGHT)

Sight Sciences (NASDAQ:SGHT) and Vaso (OTCMKTS:VASO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Profitability

This table compares Sight Sciences and Vaso’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-60.63%	-61.59%	-36.11%
Vaso	2.91%	9.49%	3.16%

Volatility and Risk

Sight Sciences has a beta of 2.42, suggesting that its share price is 142% more volatile than the S&P 500. Comparatively, Vaso has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Valuation & Earnings

This table compares Sight Sciences and Vaso”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$76.05 million	4.21	-$51.51 million	($0.90)	-6.72
Vaso	$86.77 million	0.35	$950,000.00	$0.01	17.48

Vaso has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Vaso, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Sight Sciences and Vaso, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1	3	4	0	2.38
Vaso	0	0	0	0	0.00

Sight Sciences presently has a consensus target price of $8.30, suggesting a potential upside of 37.19%. Given Sight Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe Sight Sciences is more favorable than Vaso.

Institutional & Insider Ownership

55.5% of Sight Sciences shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by insiders. Comparatively, 43.9% of Vaso shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Vaso beats Sight Sciences on 8 of the 14 factors compared between the two stocks.

About Sight Sciences

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

About Vaso

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.